NTII Neurobiological Technologies (MM)

Neurobiological Technologies, Inc. Announces Election of Dr. Ronald E. Cape to Board of Directors RICHMOND, Calif., Nov. 19 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NASDAQ:NTII), a biotechnology company engaged in the business of acquiring and developing central nervous system (CNS) related drug candidates, today announced the election of Dr. Ronald E. Cape to its board of directors at the company's annual meeting. The board now consists of 8 directors. Dr. Cape, age 72, has worked in the biotechnology industry for more than 30 years and currently serves as a consultant for several public and private biotechnology companies. He co-founded Cetus Corporation in 1971 and served as its chairman for 20 years and chief executive officer for 13 years until Cetus merged with Chiron Corporation in 1991. Cetus was a world leader and pioneer in genetic engineering, developing a technology that was ultimately awarded a Nobel Prize. He was also the founding chairman of Darwin Molecular Corporation, which was later sold to Chiroscience plc. Dr. Cape serves on the board of EntreMed, Inc. and also serves as a director for several privately held biotechnology companies, including Caprion, Inc. and Neugenesis Corp. He was a founding member of the Industrial Biotechnology Association (now the Biotechnology Industry Organization, or BIO), where he served as President from 1983 until 1985. Dr. Cape is a fellow of the American Academy of Arts and Sciences, the American Academy of Microbiology and the American Association for the Advancement of Science and has served as a board member of a number of arts and charitable organizations, including the San Francisco Opera. He has also served on the boards of Princeton University, Rockefeller University and the Whitehead Institute at MIT. He holds an AB degree from Princeton University, an MBA degree from Harvard University and a PhD degree in biochemistry from McGill University. Paul Freiman, president and CEO of NTI, said, "There are a great many business leaders who would envy Ronald Cape's achievements in the corporate world, and as many academics who would take pride in his achievements in science. It is a rare individual who can do both, and we are very pleased that Ronald's expertise in both business and biology will be available to NTI's management and shareholders." Dr. Cape said, "My career has shown me that it is not enough to have good science behind a therapy. There also has to be good business sense bringing it to the patient. The combination is not an easy one to establish, but those organizations capable of achieving that mix are the companies that flourish. I am confident that NTI is well down the path of combining solid science with sound commercial judgment, and patients all over the world stand to benefit from the company's capacities. I am glad to be a part of it." About Neurobiological Technologies, Inc. Neurobiological Technologies, Inc. is a biotechnology company engaged in the business of acquiring and developing central nervous system (CNS) related drug candidates. The company is focused on therapies for neurological conditions that occur in connection with dementia, Alzheimer's disease, ischemic stroke, neuropathic pain, and brain cancer. Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including executing on our business plan and integrating new members of our management team, as well as other risks detailed from time to time in our Securities and Exchange Commission filings. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release. We disclaim, however, any intent or obligation to update these forward-looking statements. DATASOURCE: Neurobiological Technologies, Inc. CONTACT: Paul E. Freiman, President & CEO of Neurobiological Technologies, Inc., +1-510-262-1730; or Cheryl Schneider, VP - Investor Relations, or Jeff Myhre, VP - Editorial, both of Porter, Le Vay & Rose, Inc., +1-212-564-4700, for Neurobiological Technologies, Inc. Web site: http://www.ntii.com/

Copyright